Characterization of Acute Myeloid Leukemia Patients with DEK-NUP214 Fusion Gene Positive.
10.19746/j.cnki.issn.1009-2137.2025.05.009
- Author:
Ran HUANG
1
;
Yuan-Bing WU
2
;
Ya-Xue WU
2
;
Xiao-Hui HU
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Soochow University; Suzhou 215000, Jiangsu Province, China.
2. Department of Hematology, Soochow Hopes Hematonosis Hospital, Suzhou 215000, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia
- MeSH:
Humans;
Leukemia, Myeloid, Acute/genetics*;
Poly-ADP-Ribose Binding Proteins;
Oncogene Proteins, Fusion/genetics*;
Nuclear Pore Complex Proteins/genetics*;
Oncogene Proteins/genetics*;
Chromosomal Proteins, Non-Histone/genetics*;
Male;
Female;
Adult;
Mutation;
Hematopoietic Stem Cell Transplantation;
Middle Aged
- From:
Journal of Experimental Hematology
2025;33(5):1293-1298
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical features of acute myeloid leukemia patients with DEK-NUP214 fusion gene positive.
METHODS:The DEK-NUP214 fusion gene was amplified by multi-nested PCR in 26 patients admitted to the First Affiliated Hospital of Soochow University from January 2018 to October 2023, and the disease course and post-transplant survival data were obtained by searching outpatient and inpatient medical records and telephone follow-up.
RESULTS:The median follow-up time of pateints was 21.25（0.9-60.2） months. Among 26 patients with DEK-NUP214 fusion gene positive AML, 15 patients had FLT3-ITD gene mutation positive. One patient died after abandoning treatment due to non-remission of induction chemotherapy, one died due to infection, and 23 patients received allo-HSCT after achieving CR, of which one patient died within one month after transplantation due to multiple infections and one died due to severe pulmonary infection that did not respond to treatment. One patient received allo-HSCT in non-remission state and later died due to recurrence.
CONCLUSION:DEK-NUP214 fusion gene positive AML is a type of acute leukemia subtype with high risk and poor prognosis. Allo-HSCT treatment at the early stage of disease remission is the most effective way to improve the prognosis of patients.
